8-K current report · filed Nov 5, 2026

Verastem, Inc. (VSTM) 8-K Current Report: November 5, 2026

Item 7.01Item EX-99.1VSTM overview

Short answer

Verastem, Inc. (VSTM) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation posted November 5, 2026.

Verastem, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation posted November 5, 2026
  • Exhibit 99.1 contains the presentation, potentially including updated business and investor information

Item EX-99.1 · Exhibit EX-99.1

  • Corporate presentation outlines Verastem’s commercial and development strategy in RAS/MAPK-driven cancers
  • AVMAPKI FAKZYNJA CO-PACK Q3 net product revenue $24M, with demand steady after Q2 growth
  • Blister Pack NDA received FDA Priority Review, with PDUFA decision expected February 7, 2027
  • RAMP 301 Phase 3 topline primary-endpoint readout expected mid-2027, supporting potential expansion beyond KRAS-mutant LGSOC
  • VS-7375 KRAS G12D program enrolled 190+ patients, with additional efficacy updates expected across pancreatic, colorectal and lung cancer cohorts in 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Verastem, Inc. 8-K filings

Get the next VSTM 8-K as it lands

Follow VSTM for push alerts, or ask the research agent what this filing means.